This unique service line that aligns the benefits of genomic science with value-based medicine and reimbursement models for hospitals, physician groups and payors. In addition to the clinical value of genomics for early cancer diagnosis, JTS provides genomic services that enhance the healthcare revenue cycle, address operational utilization of genomics science, and achieve Triple Aim. As reimbursement models transition from volume-based to value-based payment, JTS helps organizations realize the clinical and financial benefits of genomic testing and analytics.
Genomic testing is primarily aimed at the early detection and treatment of colorectal, lung, prostate and breast cancers. Through a strategic partnership with a leading molecular diagnostic company, JTS provides a menu of proprietary, blood-based lab tests that: